|
|
|
Profound Medical Corp (NASDAQ: PROF) |
|
Profound Medical Corp
Officers & Directors
Arun Menawat, age 71, has served as Chief Executive Officer, Director, and Chair of the Board of Profound since 2016. He previously held executive leadership positions in healthcare, including Chairman, President, and CEO of Novadaq Technologies Inc. from 2003 to 2016, and President and COO of Cedara Software. He holds a B.S. in Biology from the University of District of Columbia, a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from Northwestern University.
Rashed Dewan, age 58, has been Chief Financial Officer of Profound since March 2022. He previously served as Chief Accounting Officer and Vice President of Finance at Profound. Dewan has over 20 years of experience in finance and accounting, is a Certified Public Accountant, and holds a B.S. in Accounting from the University of Southern California.
Mathieu Burtnyk, age 44, has been President of Profound since November 2024. He has over 20 years of experience in imaging technologies and therapeutic ultrasound. Burtnyk holds a Ph.D. in Medical Biophysics from the University of Toronto and has held various leadership roles at Profound since 2011.
Tom Tamberrino, age 46, has served as Chief Commercial Officer of Profound since October 2024. He has a background in sales, marketing, and business development within the U.S. healthcare industry. Tamberrino previously was Managing Partner of AKB LLC and held sales leadership roles at LifeCell Corporation and Novadaq Technologies Inc. He holds a B.S. in Marketing with a Minor in Psychology.
Profound Medical Corp currently has 162 employees.
News about Profound Medical Corp Key Personnel |
TORONTO, July 11, 2024 - Profound Medical Corp (NASDAQ: PROF; TSX: PRN), a leading commercial-stage medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue, announced a significant development today. The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed rules that establish a Category 1 CPT code for the Transurethral Ultrasound Ablation (TULSA) procedure. This landmark decision is set to come into effect on January 1, 2025.
The introduction of the Category 1 CPT codes for the TULSA procedure is a major milestone in the field of prostate disease treatment. This coding system establishes a uniform classification for medical serv...
|
Date: January 3, 2024
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a leading medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue, recently unveiled its preliminary unaudited revenues for the fourth quarter and full year 2023. The company also shared an update on the progress it has made with the commercialization of its flagship product, TULSA-PRO, in the United States. These positive developments, showcased ahead of the planned investment community meetings and the forthcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, provide intriguing insight into Profound Medical s potential for future growth.
According to...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
